Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

General Drug Manufacturers is Zen Rated A and is the 7th ranked industry out of 146 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
BMY	BRISTOL MYERS SQUIBB CO	$117.46B	$57.52	$61.69	7.25%	Buy	16	-4.40%	16.10%	50.42%	11.70%
LLY	ELI LILLY & CO	$1.02T	$1,082.92	$1.24k	14.50%	Strong Buy	15	16.01%	23.02%	166.11%	44.45%
ABBV	ABBVIE INC	$380.57B	$215.40	$257.08	19.35%	Strong Buy	12	8.38%	108.58%	-513.26%	25.20%
AZN	ASTRAZENECA PLC	$287.57B	$185.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNY	SANOFI	$108.36B	$44.43	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIIB	BIOGEN INC	$29.08B	$196.97	$215.65	9.48%	Buy	17	1.76%	24.76%	14.81%	9.37%
PFE	PFIZER INC	$149.38B	$26.21	$29.50	12.55%	Buy	12	-4.17%	24.13%	13.72%	5.95%
AMGN	AMGEN INC	$181.37B	$336.06	$362.06	7.74%	Buy	16	2.94%	19.80%	152.97%	15.20%
JNJ	JOHNSON & JOHNSON	$556.77B	$231.29	$250.18	8.17%	Buy	17	6.51%	13.86%	45.76%	18.49%
GSK	GSK PLC	$103.75B	$51.58	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRK	MERCK & CO INC	$296.97B	$120.24	$128.60	6.95%	Buy	15	4.64%	47.61%	56.26%	20.06%
GRFS	GRIFOLS SA	$5.53B	$8.05	$10.00	24.22%	Hold	1	0.58%	26.59%	18.27%	4.89%
AMRN	AMARIN CORP PLC	$304.47M	$14.52	N/A	N/A	N/A	N/A	-3.50%	N/A	138.02%	96.05%
GILD	GILEAD SCIENCES INC	$165.99B	$133.69	$161.75	20.99%	Strong Buy	12	5.32%	19.33%	63.57%	26.56%
NVS	NOVARTIS AG	$288.35B	$151.12	$170.00	12.49%	Strong Buy	1	N/A	N/A	N/A	N/A
SCLX	SCILEX HOLDING CO	$57.83M	$6.81	N/A	N/A	N/A	N/A	156.32%	N/A	-37.16%	32.15%
NSRX	NASUS PHARMA LTD	$27.23M	$3.02	$18.50	512.58%	Buy	2	N/A	N/A	-448.49%	-248.09%
OGN	ORGANON & CO	$3.51B	$13.38	$12.00	-10.31%	Sell	3	1.00%	61.66%	111.61%	7.76%
MIRA	MIRA PHARMACEUTICALS INC	$48.54M	$1.16	N/A	N/A	N/A	N/A	N/A	N/A	-82.53%	-81.52%
MDCX	MEDICUS PHARMA LTD	$17.45M	$0.31	$9.00	2,822.08%	Strong Buy	1	N/A	N/A	2,919.95%	521.35%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in May 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 48, which is 10 points higher than the general drug manufacturer industry average of 38.

BMY passed 17 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 22.67% over the past year, underperforming other general drug manufacturer stocks by -13 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $61.69, an upside of 7.25% from Bristol Myers Squibb Co's current stock price of $57.52.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Bristol Myers Squibb Co, 37.5% have issued a Strong Buy rating, 6.25% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 6.25% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 62, which is 24 points higher than the general drug manufacturer industry average of 38.

LLY passed 25 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 49.32% over the past year, overperforming other general drug manufacturer stocks by 13 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,239.93, an upside of 14.5% from Eli Lilly & Co's current stock price of $1,082.92.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Eli Lilly & Co, 73.33% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 6.67% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Abbvie (NYSE:ABBV)

Abbvie (NYSE:ABBV) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Abbvie (NYSE:ABBV) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: C.

Abbvie (NYSE:ABBV) has a Due Diligence Score of 29, which is -9 points lower than the general drug manufacturer industry average of 38. Although this number is below the industry average, our proven quant model rates ABBV as a "B".

ABBV passed 10 out of 38 due diligence checks and has average fundamentals. Abbvie has seen its stock return 15.98% over the past year, underperforming other general drug manufacturer stocks by -20 percentage points.

Abbvie has an average 1 year price target of $257.08, an upside of 19.35% from Abbvie's current stock price of $215.40.

Abbvie stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Abbvie, 66.67% have issued a Strong Buy rating, 16.67% have issued a Buy, 16.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 4.92%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.7%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 131.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.98%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.7%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 58.1% indicates that its high dividend yield is sustainable for the long-term.

3. Astrazeneca (NYSE:AZN)

Astrazeneca (NYSE:AZN) has an annual dividend yield of 3.43%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.7%. Astrazeneca's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Astrazeneca's dividend has shown consistent growth over the last 10 years.

Astrazeneca's dividend payout ratio of 62.7% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.91% in the last day, and up 3.34% over the last week. Mira Pharmaceuticals was the among the top gainers in the drug manufacturers - general industry, gaining 18.58% yesterday.

MIRA Pharmaceuticals shares are trading higher after the company announced the execution of Amendment No. 1 to its exclusive Ketamir-2 license agreement with MIRALOGX.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 50 points higher than the general drug manufacturer industry average of 36. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has gained 53.42% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 18 percentage points.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 7 points higher than the general drug manufacturer industry average of 36. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 22.67% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -13 percentage points.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Gsk has a valuation score of 43, which is 7 points higher than the general drug manufacturer industry average of 36. It passed 3 out of 7 valuation due diligence checks.

Gsk's stock has gained 30.78% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -5 percentage points.

Are general drug manufacturer stocks a good buy now?

50% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 13.58% over the next year.

12.5% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 37.5% of general drug manufacturer stocks are rated B (Buy), 43.75% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 36.24x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.